This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NovaBay Pharmaceuticals Reports Fourth Quarter Financial Results And 2013 Clinical And Business Update

NovaBay's license and collaboration revenue for the year ended December 31, 2012 was $6.9 million, compared to $11.0 million a year ago. License and collaboration revenues for the fourth quarter ended December 31, 2012 remained relatively consistent at $1.1 million, compared to $1.2 million in the fourth quarter of 2011. The full-year decrease for 2012 compared to the same periods in 2011 is attributed to the termination in 2011 of the Alcon agreement and was partially offset by upfront licensing fees and milestones payments received in 2012 from other collaboration partners.

Total research and development expenses increased by 6.4% to $9.3 million for the year ended December 31, 2012, from $9.9 million for the year ended December 31, 2011. For the fourth quarter 2012, research and development expenses were relatively consistent at $2.1 million, compared to $2.2 million in the same quarter a year ago. This year over year decrease was primarily due to the reduction of costs associated with the 2011 termination of the Alcon agreement, partially offset by the increase in costs in NovaBay's conjunctivitis and UCBE trials.

NovaBay expects to incur increasing research and development expenses in 2013 and in subsequent years as it continues to increase its focus on developing product candidates, both independently and in collaboration with our partners. In particular, the company expects to incur ongoing clinical, chemistry, and manufacturing expenses related to four healthcare markets in which it's pursuing opportunities: ophthalmology, dermatology, urology, and advanced wound care.

General and administrative expenses increased 10.0% to $6.0 million in 2012, compared to $5.4 million in 2011, reflecting an increase in marketing and and support for the distribution of NeutroPhase. The company expects that general and administrative expenses will increase slightly as it continues to market its NeutroPhase product in 2013 and provide general support for the growth in our clinical trials.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs